MedTrace Logo

Estrogen Receptor 1 Gene Polymorphism Frequency in Fibromyalgia Syndrome

NCT03786393 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2021-09-01

No results posted yet for this study

Summary

Fibromyalgia Syndrome (FMS) is a chronic musculoskeletal disorder accompanied by diffuse body pain, increased fatigue and tenderness in specific anatomical regions, and sleep disturbance. The higher prevalence of FMS in women and the observation of it from young adulthood suggest the effect of sex hormones on the pathophysiology of this condition. Steroid hormones, especially estrogen, have effects on both the peripheral and central nervous system receptors (estrogen receptor-a \[ERa\] and estrogen receptor-b \[ERb\]), on the inflammatory process, and on central pain delivery. However, the mechanism of action of these hormonal effects is still unknown and is a matter of debate.

The fact that fibromyalgia syndrome and migraine are more common in women of reproductive age and their incidence is higher than other populations suggests that these two diseases may have a common genetic basis. Previous studies have shown that ESR-1 594G\> A (rs2228480), ESR-1 325C\> G (rs2295190) polymorphisms significantly increase the risk of migraine occurrence. However, there are no studies investigating these polymorphisms in FMS. In this study, it was aimed to investigate whether there is a relationship between ESR-1 594G\> A (rs2228480) and ESR-1 325C\> G (rs2295190) polymorphisms and fibromyalgia disease.

Conditions

  • Fibromyalgia

Interventions

DIAGNOSTIC_TEST

ACR 1990 fibromyalgia critters

ACR 1990 fibromyalgia critters

Sponsors & Collaborators

  • Nigde Omer Halisdemir University

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-11
Primary Completion
2021-04-15
Completion
2021-05-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03786393 on ClinicalTrials.gov